---
title: "Intraday News - Moderna (MRNA-US) surged 5.02%, reported at $62.75"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290977878.md"
description: "Moderna (MRNA) stock price rose 5.02% to $62.75 during intraday trading, with a trading volume of approximately 510,000 shares. On the same day, major U.S. stock indices generally declined, with the Philadelphia Semiconductor Index experiencing the largest drop of 4.99%. Moderna has increased by over 102% this year, with a rise of 27.45% in the past month"
datetime: "2026-06-26T13:56:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290977878.md)
  - [en](https://longbridge.com/en/news/290977878.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290977878.md)
---

# Intraday News - Moderna (MRNA-US) surged 5.02%, reported at $62.75

As of 21:41 Taipei time on the 26th, Moderna (MRNA-US) saw its stock price rise by $3 to $62.75, an increase of 5.02%, with a trading volume of 511,907 shares. The intraday high was $62.75 and the low was $59.23.

_U.S. Stock Index Performance_

-   Dow Jones Index: -0.56%
-   S&P 500 Index: -0.68%
-   NASDAQ Index: -1.1%
-   Philadelphia Semiconductor Index: -4.99%

_Historical Price Changes of Moderna (MRNA-US)_

-   Last week: -6.58%
-   Last month: +27.45%
-   Last 3 months: +11.6%
-   Last 6 months: +82.44%
-   Year to date: +102.61%

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)

## Related News & Research

- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases](https://longbridge.com/en/news/290822266.md)
- [Moderna’s mRNA flu vaccine passes FDA AdCom, review underway](https://longbridge.com/en/news/290435765.md)